Table 1.
Baseline Characteristics of 272 Women with Escherichia coli Pyelonephritis Treated with 7 Days of Trimethoprim-Sulfamethoxazole (TMP-SMX) versus 7 Days of Ciprofloxacin from 2010 to 2016
| Variable | TMP-SMX (n=81; 30%) |
Ciprofloxacin (n=191; 70%) |
p-value |
|---|---|---|---|
| Age (median, IQR) | 37 (29–48) | 41 (26–59) | 0.33 |
| Race/Ethnicity | |||
| Caucasian | 36 (43%) | 77 (40%) | 1.00 |
| African American | 37 (46%) | 80 (42%) | 0.59 |
| Latino | 2 (2%) | 8 (4%) | 0.73 |
| Asian/Pacific Islander | 2 (2%) | 13 (7%) | 0.24 |
| Multiracial/Unknown | 6 (7%) | 13 (7%) | 0.80 |
| Pre-existing conditions | |||
| Diabetes | 12 (15%) | 30 (16%) | 1.00 |
| Human immunodeficiency virus | 2 (2%) | 6 (3%) | 1.00 |
| Chemotherapy in past 6 months | 1 (1%) | 4 (2%) | 1.00 |
| Renal transplant | 1 (1%) | 4 (2%) | 1.00 |
| End-stage liver disease | 1 (1%) | 4 (2%) | 1.00 |
| Immunomodulators within the past 30 days | 2 (2%) | 11 (6%) | 1.00 |
| Indwelling or intermittent urinary catheterization | 2 (2%) | 6 (3%) | 1.00 |
| Serum creatinine on day of positive urine culture (median, IQR) | 1 (0.7–1) | 1 (0.8–1) | 0.22 |
| Escherichia coli bacteremia | 7 (9%) | 40 (21%) | <0.01 |
| Hospitalized | 18 (22%) | 69 (36%) | 0.01 |
| Extended spectrum beta-lactamase producing E. coli | 3 (4%) | 4 (2%) | 0.43 |